Androski Lindsay has filed 7 insider transactions across 2 companies since January 2024.
Most recent transaction: a grant/award of 28000 shares of Arbutus Biopharma Corp ($ABUS) on February 02, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Arbutus Biopharma Corp | $ABUS | Androski Lindsay | President and CEO | A | Common Shares | 28000 | $0.00 | 28,000.0000 | 192,324,017 | 9999.99% | 0.01% |
| Feb. 2, 2026 | Arbutus Biopharma Corp | $ABUS | Androski Lindsay | President and CEO | A | Stock Option (Right to Buy) | 71700 | $0.00 | 71,700.0000 | 192,324,017 | 9999.99% | 0.04% |
| March 18, 2025 | Arbutus Biopharma Corp | $ABUS | Androski Lindsay | President and CEO | A | Stock Option (Right to Buy) | 310422 | $0.00 | 310,422.0000 | 0 | 9999.99% | 0.00% |
| Jan. 24, 2025 | Eloxx Pharmaceuticals, Inc. | $ELOX | Androski Lindsay | Director | M | Common Stock | 3750 | $0.00 | 15,750.0000 | 3,758,804 | 31.25% | 0.10% |
| Jan. 24, 2025 | Eloxx Pharmaceuticals, Inc. | $ELOX | Androski Lindsay | Director | M | Restricted Stock Units | 3750 | $0.00 | 3,750.0000 | 3,758,804 | 50.00% | 0.10% |
| Oct. 16, 2024 | Eloxx Pharmaceuticals, Inc. | $ELOX | Androski Lindsay | Director | A | Common Stock | 12000 | $0.00 | 12,000.0000 | 2,570,620 | 9999.99% | 0.47% |
| Jan. 24, 2024 | Eloxx Pharmaceuticals, Inc. | $ELOX | Androski Lindsay | Director | A | Restricted Stock Units | 7500 | $0.00 | 7,500.0000 | 2,570,620 | 9999.99% | 0.29% |